ArticleJournal of cardiovascular development and disease2025
Impact of Simulated Vascular Aging and Heart Rate on Myocardial Efficiency: A Tale of Two Paradigms from In Silico Modelling.
Article in Journal of cardiovascular development and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Admission and 24-hour heart rates and in-hospital outcomes in STEMI undergoing primary PCI.BMC cardiovascular disorders · 2026Observational
- Myocardial oxygen consumption, myocardial efficiency, and mechanical efficiency: A review across pathologic and physiologic states.Physiological reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVascular aging is associated with a loss of aortic compliance (C
methodsWe used a modified computational model (CM) to assess PVA and SW and calculate MVO
resultsDuring Phase I, MyoEff-PVA increased from 20.7 to 31.2%, and MyoEff-SW increased from 14.8 to 18.9%. In Phase II, during the N setting coupled with increases in the heart rate, the MyoEff-PVA decreased from 29.4 to 14.8 to 9.5%; the MyoEff-SW also decreased from 22.5 to 10.3 to 5.9%. As expected, during the S setting, MyoEff-PVA decreased from 45.5 to 22.9 to 14.8; a similar effect occurred with the MyoEff-SW, demonstrating a decrease from 29.9 to 13.9 to 7.9%, respectively.
conclusionsThe CM provided insights into a simple and clinically relevant calculation for assessing MyoEff. The agreement on the CM metrics aligns with studies conducted previously in the clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.